In vivo magnetic resonance spectroscopy and its application to neuropsychiatric disorders

Canadian Journal of Psychiatry

Volumn 47, Issue 4, 2002, Pages 315-326

  Stanley, Jeffrey A ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Autism; Bipolar; Depression; In vivo; Phosphorus; Proton; Schizophrenia; Spectroscopy

Indexed keywords

MEMBRANE PHOSPHOLIPID; N ACETYLASPARTIC ACID;

AUTISM; BIPOLAR DEPRESSION; BRAIN MAPPING; BRAIN METABOLISM; CEREBELLUM; DIAGNOSTIC IMAGING; HIGH ENERGY PHOSPHATE; HUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PREFRONTAL CORTEX; REVIEW; SCHIZOPHRENIA; TEMPORAL CORTEX;

EID: 0036299684     PISSN: 07067437     EISSN: None     Source Type: Journal    
DOI: 10.1177/070674370204700402     Document Type: Review

References (156)

1. Magnetic resonance spectroscopy in schizophrenia: Methodological issues and findings-part 1
2. The nagging question of the function of N-acetylaspartylglutamate
3. N-acetylaspartate in neuropsychiatric disorders
4. Cellular mechanisms of brain energy metabolism and their relevance to functional brain imaging
5. In vivo nuclear magnetic resonance spectroscopy studies of the relationship between the glutamate-glutamine neurotransmitter cycle and functional neuroenergetics
6. Absolute concentrations of metabolites in the adult human brain in vivo: Quantification of localized proton MR spectra
7. Localized proton NMR spectroscopy in different regions of the human brain in vivo. Relaxation times and concentrations of cerebral metabolites
8. Transport of energy in muscle: The phosphorylcreatine shuttle
9. Intracellular compartmentation, structure and function of creatine kinase isoenzymes in tissues with high and fluctuating energy demands: The 'phosphocreatine circuit' for cellular energy homeostasis
10. Enzymatic pathways of phospholipid metabolism in the nervous system
11. 31P nuclear magnetic resonance studies of phosphoglyceride metabolism in developing and degenerating brain: Preliminary observations
12. Elevated phosphocholine and phosphatidyl choline following rat entorhinal cortex lesions
13. 1H NMR spectroscopy: N-acetyl-1-aspartate, creatine and choline
14. 1H spectroscopic imaging of the human brain at 4.1 T
15. 1H magnetic resonance spectroscopy at 0.5 tesla
16. Comparison of the quantification precision of human short echo time (1)h spectroscopy at 1.5 and 4.0 tesla
17. Single-voxel proton MRS of the human brain at 1.5T and 3.0T
18. 1H NMR spectroscopy of the human brain at 7 T
19. Spatial localization in NMR spectroscopy in vivo
20. Image-selected in vivo spectroscopy (ISIS). A new technique for spatially selective NMR spectroscopy
21. 31P NMR spectroscopy of the adult human brain in vivo using stimulated-echo (STEAM) sequences
22. Short TE phosphorus spectroscopy using a spin-echo pulse
23. Practical applications of chemical shift imaging
24. 31P brain spectra
25. Endoplasmic reticulum: The major contributor to the pde peak in hepatic 31P-NMR spectra at low magnetic field strengths
26. 31P NMR spectra in vivo
27. 31P NMR spectrum of human brain. The determination of the concentrations of phosphodiester components
28. 31P-NMR study of brain phospholipid structures in vivo
29. Alterations of cerebral metabolism in probable Alzheimer's disease: A preliminary study
30. Synthesis of N-acetyl-1-aspartate by rat brain mitochondria and its involvement in mitochondrial/cytosolic carbon transport
31. N-acetylation of 1-aspartate in the nervous system: Differential distribution of a specific enzyme
32. N-acetyl-aspartyl-glutamate: Regional levels in rat brain and the effects of brain lesions as determined by a new hplc method
33. Immunocytochemical localization of N-acetyl-aspartate with monoclonal antibodies
34. N-acetyl-1-aspartic acid content of human neural tumours and bovine peripheral nervous tissues
35. Immunohistochemical localization of N-acetylaspartate in rat brain
36. Proton nuclear magnetic resonance spectroscopy unambiguously identifies different neural cell types
37. Aspartoacylase deficiency and N-acetylaspartic aciduria in patients with Canavan disease
38. The molecular basis of canavan (aspartoacylase deficiency) disease in European non-Jewish patients
39. Canavan disease. Analysis of the nature of the metabolic lesions responsible for development of the observed clinical symptoms
40. Reversible decreases in N-acetylaspartate after acute brain injury
41. Reversal of abnormalities of myelination by thyroxine therapy in congenital hypothyroidism: Localized in vivo proton magnetic resonance spectroscopy (MRS) study
42. In vitro expression of N-acetyl aspartate by oligodendrocytes: Implications for proton magnetic resonance spectroscopy signal in vivo
43. Intraneuronal N-acetylaspartate supplies acetyl groups for myelin lipid synthesis: Evidence for myelin-associated aspartoacylase
44. Developmental and regional distribution of aspartoacylase in rat brain tissue
45. Functions of N-acetyl-1-aspartate and N-acetyl-1-aspartylglutamate in the vertebrate brain: Role in glial cell-specific signaling
46. Evidence supporting a role for N-acetyl-1-aspartate as a molecular water pump in myelinated neurons in the central nervous system. An analytical review
47. Proton NMR chemical shifts and coupling constants for brain metabolites
48. 1H NMR measurements of gamma-aminobutyric acid in human brain in vivo
49. Yield enhancement of a double-quantum filter sequence designed for the edited detection of gaba
50. In vivo detection of gaba in human brain using a localized double-quantum filter technique
51. Metabolite-specific NMR spectroscopy in vivo
52. Simultaneous spectral editing for gamma-aminobutyric acid and taurine using double quantum coherence transfer
53. Reduced cortical gamma-aminobutyric acid levels in depressed patients determined by proton magnetic resonance spectroscopy
54. Impairment of gabaergic transmission in depression: New insights from neuroimaging studies
55. Reductions in occipital cortex gaba levels in panic disorder detected with 1H-magnetic resonance spectroscopy
56. Detection of glutathione in the human brain in vivo by means of double quantum coherence filtering
57. Glutathione
58. Free radical pathology and antioxidant defense in schizophrenia: A review
59. A unified hypothesis of schizophrenia based on glutathione deficit
60. A unitary model of schizophrenia bleuler's "fragmented phrene" as schizencephaly
61. MRI anatomy of schizophrenia
62. Schizophrenia, the heteromodal association neocortex and development: Potential for a neurogenetic approach
63. Hypofrontality in neuroleptic-naive patients and in patients with chronic schizophrenia. Assessment with xenon 133 single-photon emission computed tomography and the tower of london
64. Neurochemical sensitization in the pathophysiology of schizophrenia: Deficits and dysfunction in neuronal regulation and plasticity
65. The glutamate synapse in neuropsychiatric disorders. Focus on schizophrenia and alzheimer's disease
66. Development, disease and degeneration in schizophrenia: A unitary pathophysiological model
67. Schizophrenia and disordered neural circuitry
68. Essential fatty acids, lipid membrane abnormalities, and the diagnosis and treatment of schizophrenia
69. Is schizophrenia a neurodevelopmental disorder?
70. From neuropathology to neurodevelopment
71. The neurodevelopmental hypothesis of schizophrenia: Following a trail of evidence from cradle to grave
72. Schizophrenia and late maturational brain changes in man
73. Parallel distributed processing and the emergence of schizophrenic symptoms
74. Is schizophrenia due to excessive synaptic pruning in the prefrontal cortex?
75. Alterations in brain high-energy phosphate and membrane phospholipid metabolism in first-episode, drug-naive schizophrenics. A pilot study of the dorsal prefrontal cortex by in vivo phosphorus 31 nuclear magnetic resonance spectroscopy
76. The reduced neuropil hypothesis: A circuit based model of schizophrenia
77. Localized phosphorus 31 magnetic resonance spectroscopy in chronic schizophrenic patients and normal controls
78. An in vivo study of the prefrontal cortex of schizophrenic patients at different stages of illness via phosphorus magnetic resonance spectroscopy
79. Changes in levels of phosphorus metabolites in temporal lobes of drug-naive schizophrenic patients
80. 1H MRSI study
81. 31P chemical shift imaging study of medicated schizophrenic patients and healthy controls
82. Magnetic resonance spectroscopy in schizophrenia: Methodological issues and findings-part II
83. 31P nuclear magnetic resonance spectroscopy: Neurodevelopment and schizophrenia
84. Cerebral phosphate metabolism in first-degree relatives of patients with schizophrenia
85. 31P MRS study
86. An in vivoproton magnetic resonance spectroscopy study of schizophrenia patients
87. Measurement of glutamate and glutamine in the medial prefrontal cortex of never-treated schizophrenic patients and healthy controls by proton magnetic resonance spectroscopy
88. A short echo proton magnetic resonance spectroscopy study of the left mesial-temporal lobe in first-onset schizophrenic patients
89. Estimation of metabolite concentrations from localized in vivo proton NMR spectra
90. 1H MR spectra
91. 1H MR spectra: Prior knowledge, peak elimination, and filtering
92. Proton magnetic resonance spectroscopy in the frontal and temporal lobes of neuroleptic naive patients with schizophrenia
93. Progressive brain volume changes and the clinical course of schizophrenia in men: A longitudinal magnetic resonance imaging study
94. Mapping adolescent brain change reveals dynamic wave of accelerated gray matter loss in very early-onset schizophrenia
95. Structural changes in the brain of patients with bipolar affective disorder by MRI: A review of the literature
96. An MRI study of temporal lobe structures in men with bipolar disorder or schizophrenia
97. Functional neuroimaging studies of depression: The anatomy of melancholia
98. The role of functional neuroimaging in the neuropsychology of depression
99. Neuroimaging in bipolar disorder
100. The anatomy of mood disorders-review of structural neuroimaging studies
101. Subcortical signal hyperintensities in bipolar patients detected by MRI
102. T2 hyperintensities in bipolar disorder: Magnetic resonance imaging comparison and literature meta-analysis
103. Anterior paralimbic mediation of procaine-induced emotional and psychosensory experiences
104. SPECT PET imaging in mood disorders
105. The functional neuroanatomy of mood disorders
106. Brain phosphorous metabolism in depressive disorders detected by phosphorus-31 magnetic resonance spectroscopy
107. 31P and 7Li magnetic resonance spectroscopy
108. Abnormal frontal lobe phosphorous metabolism in bipolar disorder
109. Decreased temporal lobe phosphomonoesters in bipolar disorder
110. Measurement of brain phosphoinositide metabolism in bipolar patients using in vivo 31P-MRS
111. Lateralized abnormality of high energy phosphate metabolism in the frontal lobes of patients with bipolar disorder detected by phase-encoded 31P-MRS
112. Reduction of brain phosphocreatine in bipolar II disorder detected by phosphorus-31 magnetic resonance spectroscopy
113. Proton magnetic resonance spectroscopy of the brain in schizophrenic and affective patients
114. Choline-containing compounds detected by proton magnetic resonance spectroscopy in the basal ganglia in bipolar disorder
115. Quantitative proton magnetic resonance spectroscopy of the basal ganglia in patients with affective disorders
116. Choline, myo-inositol and mood in bipolar disorder: A proton magnetic resonance spectroscopic imaging study of the anterior cingulate cortex
117. Proton magnetic resonance spectroscopy of the lenticular nuclei in bipolar i affective disorder
118. Decreased dorsolateral prefrontal N-acetyl aspartate in bipolar disorder
119. Increased thalamic N-acetylaspartate in male patients with familial bipolar i disorder
120. 31P nuclear magnetic resonance spectroscopy findings in bipolar illness: A meta-analysis
121. Phosphorus-31 magnetic resonance spectroscopy and ventricular enlargement in bipolar disorder
122. Magnetic resonance spectroscopy in affective disorders
123. Inositol phosphates and cell signalling
124. Neural and developmental actions of lithium: A unifying hypothesis
125. Lithium amplifies agonist-dependent phosphatidylinositol responses in brain and salivary glands
126. Proton MR spectroscopy in children with bipolar affective disorder: Preliminary observations
127. Decreased anterior cingulate myo-inositol/creatine spectroscopy resonance with lithium treatment in children with bipolar disorder
128. 31P magnetic resonance spectroscopy in the frontal lobe of major depressed patients
129. Lower levels of nucleoside triphosphate in the basal ganglia of depressed subjects: A phosphorous-31 magnetic resonance spectroscopy study
130. 31P-MRS study of aceryl-1-carnitine treatment in geriatric depression: Preliminary results
131. Reduced glutamate in the anterior cingulate cortex in depression: An in vivo proton magnetic resonance spectroscopy study
132. Functional neuroimaging of autistic disorders
133. Neuropathology of infantile autism
134. An MRI study of brain size in autism
135. Magnetic resonance imaging in autism: Measurement of the cerebellum, pons, and fourth ventricle
136. Unusual brain growth patterns in early life in patients with autistic disorder: An MRI study
137. Macrocephaly in children and adults with autism
138. Development of the hippocampal formation from 2 to 42 years: MRI evidence of smaller area dentata in autism
139. 31P MRS study of autism: Evidence for undersynthesis and increased degradation of brain membranes
140. Differences in brain metabolites between patients with autism and mental retardation as detected by in vivo localized proton magnetic resonance spectroscopy
141. Brain metabolites in the hippocampus-amygdala region and cerebellum in autism: An 1H-MR spectroscopy study
142. Evidence of altered energy metabolism in autistic children
143. Regional magnetic resonance spectroscopy of the brain in autistic individuals
144. Magnetic resonance imaging abnormalities in lenticular nuclei and cerebral cortex in schizophrenia
145. A quantitative magnetic resonance imaging study of changes in brain morphology from infancy to late adulthood
146. The human brain age 7-11 years: A volumetric analysis based on magnetic resonance images
147. Brain development, gender and IQ in children. A volumetric imaging study
148. Brain development during childhood and adolescence: A longitudinal MRI study
149. 31P MRS
150. Sex differences in brain maturation during childhood and adolescence
151. Frontal lobe in vivo 31P-MRS reveals gender differences in healthy controls, not in schizophrenics
152. Magnetic resonance spectroscopy of the human brain